Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Authors :: Ran Reshef
Olalekan O. Oluwole
John M. Rossi
Remus Vezan
Mauro P. Avanzi
Yin Yang
Wayne R. Godfrey
Vicki Plaks
David G. Maloney
Jennifer Lee
Alison R. Sehgal
Lovely Goyal
Sven de Vos
Caron A. Jacobson
Javier Munoz
Pashna N. Munshi
Ibrahim Yakoub-Agha
Lori A. Leslie
Henry C. Fung
Basem M. William
Julio C. Chavez
Gilles Salles
Sattva S. Neelapu
Carla Casulo
Joseph D. Rosenblatt
Source :: Transplantation and Cellular Therapy. 27:S67-S68
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
Transplantation
medicine.medical_specialty
business.industry
Phases of clinical research
Cell Biology
Hematology
Internal medicine
Relapsed refractory
Indolent Non-Hodgkin Lymphoma
Molecular Medicine
Immunology and Allergy
Medicine
In patient
business

Full Text Access

Tools